➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Baxter
Harvard Business School
Merck
Johnson and Johnson

Last Updated: August 4, 2020

DrugPatentWatch Database Preview

DESYREL Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Desyrel, and what generic alternatives are available?

Desyrel is a drug marketed by Pragma and is included in one NDA. There is one patent protecting this drug.

This drug has thirty patent family members in twenty-two countries.

The generic ingredient in DESYREL is trazodone hydrochloride. There are fourteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the trazodone hydrochloride profile page.

Drug patent expirations by year for DESYREL
Drug Sales Revenue Trends for DESYREL

See drug sales revenues for DESYREL

Recent Clinical Trials for DESYREL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Phase 3
University of WashingtonPhase 3
Centre hospitalier de l'Université de Montréal (CHUM)Phase 4

See all DESYREL clinical trials

Paragraph IV (Patent) Challenges for DESYREL
Tradename Dosage Ingredient NDA Submissiondate
DESYREL TABLET;ORAL trazodone hydrochloride 018207

US Patents and Regulatory Information for DESYREL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pragma DESYREL trazodone hydrochloride TABLET;ORAL 018207-001 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial Y Y   Start Trial
Pragma DESYREL trazodone hydrochloride TABLET;ORAL 018207-004 Nov 7, 1988 DISCN Yes No   Start Trial   Start Trial Y Y   Start Trial
Pragma DESYREL trazodone hydrochloride TABLET;ORAL 018207-002 Approved Prior to Jan 1, 1982 DISCN Yes No   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Mallinckrodt
Moodys
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.